ALYSSA LOEPKER: Open Payments
NPI 1992194401 · HIGHLAND, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$979 in 61 payments from 10 companies in 2025. Trend: 2023 $551 · 2024 $1,157 · 2025 $979
Food & beverage: $979
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $252 |
| AstraZeneca Pharmaceuticals LP | 8 | $235 |
| Novo Nordisk Inc | 20 | $215 |
| Lilly USA, LLC | 4 | $86 |
| GlaxoSmithKline, LLC. | 3 | $62 |
| Janssen Pharmaceuticals, Inc | 3 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| PFIZER INC. | 1 | $19 |
| Amgen Inc. | 1 | $15 |
Products named: FARXIGA, QULIPTA, Ozempic, MOUNJARO, VRAYLAR, Rybelsus, Wegovy, SPRAVATO.
Industry payments across IL — which companies pay providers there.
